Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This pilot study hypothesizes that hyperthermia delivered via magnetic resonance-guided
focused ultrasound (MRg-FU) is technically feasible and can be safely used in combination
with concurrent reirradiation and chemotherapy for the treatment of recurrent rectal cancer.
Twenty recurrent rectal cancer patients who are not candidates for surgery will be recruited
for hyperthermia treatment delivered via MRg-FU concurrent with reirradiation and oral
chemotherapy.